Teriparatide

Teriparatide binds PTH1R (a class B GPCR) on osteoblasts and osteocytes, activating Gs (cAMP/PKA) and Gq (PLC/IP3/Ca2+) pathways. Brief daily exposure activates anabolic pathways: Wnt signaling (by reducing sclerostin and DKK1 production from osteocytes), reduced osteoblast apoptosis (via Bcl-2 upregulation), and increased bone matrix protein synthesis. The key is pulse kinetics, brief receptor activation before cAMP desensitizes preserves net anabolic signaling, distinguishing intermittent from continuous PTH effects.

Initially (first 1-3 months), teriparatide stimulates both bone formation and resorption, with a net positive balance because formation precedes resorption in the remodeling cycle. By months 6-24, bone mineral density (BMD) increases 8-14% at the lumbar spine and 3-6% at the hip. The increased bone volume involves both trabecular connectivity restoration and cortical bone periosteal expansion. Biochemical markers of bone formation (P1NP, osteocalcin) rise within 1-2 months, preceding antiresorptive marker decreases.

PTH1R activation accelerates fracture healing by stimulating callus formation, endochondral ossification, and woven bone mineralization. In animal models, teriparatide treatment reduces fracture healing time by 25-40% and produces mechanically superior callus. Human studies in hip fracture, distal radius fracture, and pelvic insufficiency fracture show trends toward faster radiographic healing and faster functional recovery, though definitive Phase III fracture healing trials are limited.

The pivotal FPT trial showed teriparatide 20 mcg/day reduced vertebral fractures by 65% and non-vertebral fractures by 53% versus placebo over 18 months. Lumbar spine BMD increased 9.7%. These results established teriparatide as superior to antiresorptives for severe osteoporosis with prevalent fractures. Sequential therapy with antiresorptives after teriparatide is essential to preserve anabolic gains.

Multiple RCTs and observational studies support faster fracture healing with teriparatide in hip fracture (reduced time to weight bearing), distal radius fracture, pelvic insufficiency fractures, and stress fractures in athletes. A 2018 Cochrane review noted promising signals but insufficient evidence for definitive recommendations. Off-label use for fracture healing is common in clinical practice, particularly for difficult or non-union fractures.

Research interest exists in teriparatide for exercise performance via its anabolic bone and potentially muscle effects (PTH1R is expressed on skeletal muscle). Short courses have been studied in athletes with stress fractures, showing faster return-to-sport. The anabolic effect on bone without systemic nitrogen retention or virilization distinguishes it from anabolic steroids, though its clinical application in performance contexts is outside approved indications.